Additional Relevant Details Data from a Phase 2 study of Arhalofenate was recently released showing positive data from the trial.  However, phase 3 studies will not begin until CymaBay secures a commercial partner for the studies.  Gout is predominately treated by primary care physicians. Therefore, partnering arhalofenate with one or more companies that have a presence in the primary care market is a priority for the Company.  According to a press release, CymaBay is in ongoing discussions with potential partners.